EP2010215A4 - Uses and compositions for treatment of crohn's disease - Google Patents
Uses and compositions for treatment of crohn's diseaseInfo
- Publication number
- EP2010215A4 EP2010215A4 EP07755288A EP07755288A EP2010215A4 EP 2010215 A4 EP2010215 A4 EP 2010215A4 EP 07755288 A EP07755288 A EP 07755288A EP 07755288 A EP07755288 A EP 07755288A EP 2010215 A4 EP2010215 A4 EP 2010215A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- crohn
- disease
- compositions
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13173241.4A EP2666480A3 (en) | 2006-04-10 | 2007-04-10 | Uses and compositions for treatment of Crohn's desease |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79090906P | 2006-04-10 | 2006-04-10 | |
US80285806P | 2006-05-22 | 2006-05-22 | |
US80261606P | 2006-05-22 | 2006-05-22 | |
US80977006P | 2006-05-30 | 2006-05-30 | |
US81548906P | 2006-06-20 | 2006-06-20 | |
US84996706P | 2006-10-06 | 2006-10-06 | |
US90463707P | 2007-03-01 | 2007-03-01 | |
US90462607P | 2007-03-01 | 2007-03-01 | |
US91817407P | 2007-03-14 | 2007-03-14 | |
PCT/US2007/008962 WO2007120720A2 (en) | 2006-04-10 | 2007-04-10 | Uses and compositions for treatment of crohn's disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13173241.4A Division EP2666480A3 (en) | 2006-04-10 | 2007-04-10 | Uses and compositions for treatment of Crohn's desease |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2010215A2 EP2010215A2 (en) | 2009-01-07 |
EP2010215A4 true EP2010215A4 (en) | 2010-06-16 |
Family
ID=38610153
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07755288A Withdrawn EP2010215A4 (en) | 2006-04-10 | 2007-04-10 | Uses and compositions for treatment of crohn's disease |
EP13173241.4A Withdrawn EP2666480A3 (en) | 2006-04-10 | 2007-04-10 | Uses and compositions for treatment of Crohn's desease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13173241.4A Withdrawn EP2666480A3 (en) | 2006-04-10 | 2007-04-10 | Uses and compositions for treatment of Crohn's desease |
Country Status (3)
Country | Link |
---|---|
EP (2) | EP2010215A4 (en) |
CA (1) | CA2564435A1 (en) |
WO (1) | WO2007120720A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8722860B2 (en) * | 2009-04-16 | 2014-05-13 | Abbvie Biotherapeutics Inc. | Anti-TNF-α antibodies and their uses |
NZ703394A (en) * | 2012-06-04 | 2017-01-27 | Centre For Digestive Diseases | Compositions and methods for treating crohn’s disease and related conditions and infections |
US10946091B2 (en) | 2012-06-04 | 2021-03-16 | Gaurav Agrawal | Compositions and methods for treating Crohn's disease and related conditions and infections |
CN106170298B (en) | 2013-10-16 | 2024-01-09 | 前瞻疗法公司 | Buffer formulations for improving antibody stability |
EP3247718B1 (en) | 2015-01-21 | 2021-09-01 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
JP7084308B2 (en) | 2016-02-03 | 2022-06-14 | アウトルック セラピューティクス,インコーポレイティド | Buffer formulation to increase antibody stability |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
US6498237B2 (en) | 1989-08-07 | 2002-12-24 | Peptech Limited | Tumor necrosis factor antibodies |
WO1991003553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | TUMOR NECROSIS FACTOR-α AND -β RECEPTORS |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0585287T3 (en) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Process for producing specific binding pair elements |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
ES2330052T3 (en) | 1991-03-01 | 2009-12-03 | Dyax Corporation | CHEMICAL PROTEIN THAT INCLUDES MICRO-PROTEINS THAT HAVE TWO OR MORE DISULFURENT BRIDGES AND RELATIONSHIPS OF THE SAME. |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
DE69233750D1 (en) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Libraries of heterodimeric receptors using phagemids |
DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5605923A (en) | 1992-04-02 | 1997-02-25 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
CA2123593C (en) | 1992-09-15 | 2000-03-14 | Craig A. Smith | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
HU228630B1 (en) | 1996-02-09 | 2013-04-29 | Abbott Biotech Ltd | Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
AU2002256971B2 (en) | 2000-12-28 | 2008-04-03 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
TW201705980A (en) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | Multiple-variable dose regimen for treating TNF[alpha]-related disorders |
IT1395574B1 (en) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | DISTRIBUTION DEVICE |
-
2006
- 2006-10-30 CA CA002564435A patent/CA2564435A1/en not_active Abandoned
-
2007
- 2007-04-10 EP EP07755288A patent/EP2010215A4/en not_active Withdrawn
- 2007-04-10 EP EP13173241.4A patent/EP2666480A3/en not_active Withdrawn
- 2007-04-10 WO PCT/US2007/008962 patent/WO2007120720A2/en active Search and Examination
Non-Patent Citations (11)
Title |
---|
D'HAENS GEERT ET AL: "Advances in medical therapy for Crohn's disease.", CURRENT GASTROENTEROLOGY REPORTS DEC 2004 LNKD- PUBMED:15527680, vol. 6, no. 6, December 2004 (2004-12-01), pages 496 - 505, XP002580099, ISSN: 1522-8037 * |
HANAUER ET AL: "A randomized, double-blind, placebo-controlled trial of the human anti-TNF-alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA LNKD- DOI:10.1053/J.GASTRO.2004.05.010, vol. 127, no. 1, 1 July 2004 (2004-07-01), pages 332, XP002580094, ISSN: 0016-5085 * |
HANAUER ET AL: "Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn's Disease: the CLASSIC-I Trial", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA LNKD- DOI:10.1053/J.GASTRO.2005.11.030, vol. 130, no. 2, 1 February 2006 (2006-02-01), pages 323 - 333, XP005284535, ISSN: 0016-5085 * |
HANAUER S B ET AL: "Rapid response to human anti-TNF monoclonal antibody adalimumab in patients with moderate to severely active Crohn's disease in the CLASSIC study", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 100, no. 9, Suppl. S, 850, September 2005 (2005-09-01), & 70TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; HONOLULU, HI, USA; OCTOBER 30 -NOVEMBER 02, 2005, pages S313 - S314, XP002580097, ISSN: 0002-9270 * |
PANACCIONE ET AL: "Advances in medical therapy of inflammatory bowel disease", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 5, no. 6, 1 December 2005 (2005-12-01), pages 566 - 572, XP005134765, ISSN: 1471-4892 * |
PAPADAKIS KONSTANTINOS A ET AL: "Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 100, no. 1, January 2005 (2005-01-01), pages 75 - 79, XP002580098, ISSN: 0002-9270 * |
SANDBORN WILLIAM ET AL: "Adalimumab, a human anti-TNF-alpha monoclonal antibody, induces clinical remission and response in patients with moderate to severely active Crohn's Disease irrespective of smoking status", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 99, no. 10, Suppl. S, 800, October 2004 (2004-10-01), & 69TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; ORLANDO, FL, USA; OCTOBER 29 -NOVEMBER 03, 2004, pages S259 - S260, XP002580096, ISSN: 0002-9270 * |
SANDBORN WILLIAM ET AL: "Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6-month open-label period with fully human anti-TNF-a monoclonal antibody adalimumab (humira((R)))", GASTROENTEROLOGY, vol. 128, no. 4, Suppl. 2, 723, April 2005 (2005-04-01), & ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION/DIGEST IVE-DISEASE-WEEK; CHICAGO, IL, USA; MAY 14 -19, 2005, pages A111 - A112, XP002580095, ISSN: 0016-5085 * |
SANDBORN WILLIAM J ET AL: "An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease", AMERICAN JOURNAL OF GASTROENTEROLOGY, ELSEVIER SCIENCE INC, US LNKD- DOI:10.1111/J.1572-0241.2004.40462.X, vol. 99, no. 10, 1 October 2004 (2004-10-01), pages 1984 - 1989, XP002477488, ISSN: 0002-9270 * |
SANDBORN WILLIAM J ET AL: "Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: Results of a blinded, placebo-controlled study", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 100, no. 9, Suppl. S, 843, September 2005 (2005-09-01), & 70TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; HONOLULU, HI, USA; OCTOBER 30 -NOVEMBER 02, 2005, pages S311, XP002580092, ISSN: 0002-9270 * |
SANDBORN WILLIAM J ET AL: "Remission and clinical response induced and maintained in patients with active Crohn's disease treated for 1-year open-label with adalimumab", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 100, no. 9, Suppl. S, 858, September 2005 (2005-09-01), & 70TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; HONOLULU, HI, USA; OCTOBER 30 -NOVEMBER 02, 2005, pages S316 - S317, XP002580093, ISSN: 0002-9270 * |
Also Published As
Publication number | Publication date |
---|---|
EP2010215A2 (en) | 2009-01-07 |
EP2666480A3 (en) | 2014-07-30 |
EP2666480A2 (en) | 2013-11-27 |
CA2564435A1 (en) | 2007-10-10 |
WO2007120720A2 (en) | 2007-10-25 |
WO2007120720A3 (en) | 2007-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2152318A4 (en) | Uses and compositions for treatment of psoriasis and crohn's disease | |
EP2069768A4 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
EP2297341A4 (en) | Methods and compositions for the treatment of huntington's disease | |
HK1134679A1 (en) | Compositions and methods for the treatment of infections | |
PL3398606T3 (en) | Microalgae-derived compositions for improving the health and appearance of skin | |
GB0522311D0 (en) | Pharmaceutical compositions for the treatment of pain | |
EP2007385A4 (en) | Cardiovascular composition and use the same for the treatment of alzheimers disease | |
EP2201370A4 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
IL197275A0 (en) | Pharmaceutical compositions of clonazepam and methods of use thereof | |
ZA200801706B (en) | Methods and compositions for the prevention and treatment of kidney disease | |
EP2001503A4 (en) | Diagnosis and treatment of alzheimer's disease | |
ZA200800452B (en) | Methods and compositions for the prevention and treatment of kidney disease | |
EP2063859A4 (en) | Cosmetic composition for the treatment of skin and methods thereof | |
IL198723A0 (en) | Methods and compositions for therapeutic treatment | |
ZA200800448B (en) | Methods and compositions for the prevention and treatment of inflammatory disease | |
EP2217238A4 (en) | Methods and compositions for the treatment of proteinuric diseases | |
ZA200708819B (en) | Methods and compositions for the prevention and treatment of kidney disease | |
EP1954800A4 (en) | Composition and use of phyto-percolate for treatment of disease | |
EP2010215A4 (en) | Uses and compositions for treatment of crohn's disease | |
GB0909297D0 (en) | Composition for the treatment of skin conditions | |
IL187405A0 (en) | Methods and compositions for the treatment of pain | |
EP1930017A4 (en) | Composition effective for prevention and treatment of adult disease | |
EP1928247A4 (en) | Composition and use of phyto-percolate for treatment of disease | |
EP2231148A4 (en) | Pharmaceutical composition for the treatment and prevention of cardiac disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081110 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1126673 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100520 |
|
17Q | First examination report despatched |
Effective date: 20110615 |
|
RAX | Requested extension states of the european patent have changed |
Extension state: HR Payment date: 20081110 Extension state: RS Payment date: 20081110 Extension state: MK Payment date: 20081110 Extension state: BA Payment date: 20081110 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ABBVIE BIOTECHNOLOGY LTD |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20141031 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1126673 Country of ref document: HK |